Q2 INTERRIM REPORT JANUARY – JUNE 2016 NICOCCINO HOLDING

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Q2 INTERRIM REPORT JANUARY – JUNE 2016 NICOCCINO HOLDING AB (publ)

Nicoccino Holding Development SECOND QUARTER SUMMARY APRIL – JUNE 2016 ·      Net sales for the second quarter amounted to 53 TSEK (397 TSEK). ·      Net income amounted to -4.9 MSEK (-7.4 MSEK) or -0.35 SEK per share ( -0.56 SEK). ·      Cash flow from operating activities amounted to 1.2 MSEK (-7.4 MSEK) or 0.08 SEK per share (-0.56 SEK). ·      Liquid assets amounted to 28.1 MSEK (50.0 MSEK) by the end of the period. ·      The Company continues its strategy of achieving a drug classification of the nicotine film and is focused to find a suitable partner to help support this work. ·      In June, a campaign was conducted online where the Company sold out products with short shelf life. The customers answered well to the campaign and a majority of the stock was sold out. PERIOD SUMMARY JANUARY – JUNE 2016 ·      Net sales amounted to 235 TSEK (522 TSEK). ·      Net income amounted to -13.9 MSEK (-16.2 MSEK) or -1.01 SEK per share ( -1.33 SEK). ·      Cash flow from operating activities amounted to -8.1 MSEK (-15.2 MSEK) or -0.59 SEK per share (-1.25 SEK). EVENTS AFTER THE END OF THE REPORTING PERIOD ·      No significant events after the end of the period. Comments from CEO The Company’s focus In line with our strategy, we continue the journey towards a drug classification of Nicoccino™ and focus our resources towards this goal. As mentioned in previous report, the company has undergone an organizational change this spring by having closed down the London office, and this change proceeds in the form of reduced costs for the company. This allows us greater opportunities to make active choices instead of forced decisions. Sales The physical sales instore were closed down during the first quarter this year, however the online sales is still ongoing. We will continue with the online sales as long as we have goods in stock and it is my assessment that we will cover the consumer needs throughout the year. Sales during the second quarter was dominated by a campaign where products with short shelf life were sold out. It was a successful campaign and almost the entire stock where completed. It is encouraging to see such a strong interest among existing users. Production and Development During the spring, the Company was in contact with several producers having GMP standard. We are in close contact with manufacturers both in Europe and US, however most important is to continue with a producer having significant experience in producing pharmaceuticals and especially products with our characteristics. We are hopeful to start producing nicotine strips according to pharmaceutical standards later this year, and then move into the clinical study. Future expectations Our plan is to initiate the clinical study during the first quarter of 2017 and until then put all resources in producing nicotine strips according to pharmaceutical standards. The preparations for a clinical study are numerous and contain massive documentation and technical work where equipment test runs and laboratory work are performed. When completed, we produce a clinical batch for which the study is based on. The purpose of classifying the nicotine strip as a drug is obvious, to increase shareholder value and to add value into the company. A drug classification will create a clear regulatory resident, making the product more attractive for other global players active in the field of future smoking cessation products About Nicoccino and our product ABOUT THE COMPANY Nicoccino has developed an innovative and patented nicotine product that after completion of a clinical study will be classified as a medicine for smoking cessation (Nicotine Replacement Therapy – NRT). With a clear classification, regulatory uncertainty will be reduced and new markets will open up that would otherwise not be accessible. Sales to consumers will be managed indirectly through a license model with international partners who are more financially equipped to reach out globally. In 2014/2015 a commercial test launch was conducted in the UK where Nicoccino™ was sold as a consumer product online, and in retail. This introduction confirmed that the concept works and that there is a great potential for this new type of nicotine product. In early 2016 a new strategy was formed with an increased focus on creating a product platform that can be used by partners who wish to establish themselves in the market of Nicotine Replacement Therapy (NRT) or want to expand their existing product portfolio. This new strategy has resulted in the prioritization of achieving a drugs classification for when entering partnerships. Nicoccino has its office located in Täby, outside of Stockholm. The company's shares are listed on Nasdaq Stockholm First North since June 2014 and can be found under the abbreviation NICO. Remium Nordic AB is the Nicoccino’s certified adviser. For further information, please visit: www.nicoccino.se/en ABOUT THE PRODUCT Nicoccino has developed a patented, innovative and discrete strip that through its unique delivery method instantly provides the user with nicotine without the detrimental side effects of smoking. The product is designed to offer smokers an attractive alternative when they want to quit smoking. After a pharmaceutical approval, the product will be sold as a smoking cessation drug (Nicotine Replacement Therapy – NRT). Once the strip is placed under the lip and onto the gum, it delivers a quick and potent nicotine effect. Within a couple of minutes the nicotine has been expended and the film dissolves without leaving any residue in your mouth. The platform is formulated in Sweden and is the result of over ten years of research and development. The strip itself is leaf thin and alginate based, about half the size of a stamp. Each dose contains 1 mg of medically classified nicotine, an alginate base (extracted from brown seaweed), as well as natural flavorings and aromas. All additional substances are medically approved. For more information, visit Nicoccino’s website www.nicoccino.se/en, or contact: Johan Cram, CEO Nicoccino Holding AB +46 708 980 418 johan.cram@nicoccino.se The information Nicoccino Holding AB (publ) releases is provided according to financial regulations for the stock market and/or the law for trade with financial instruments. The information is prepared to be published on 26th Aug 2016, 08:00am. The report has to be communicated in Swedish and English. If differences between the versions exist, the Swedish version is pertained. Johan Cram CEO +46 708-980 418 johan.cram@nicoccino.se Nicoccino has developed a patented, innovative and discrete strip that through its unique delivery method instantly provides the user with nicotine without the detrimental side effects of smoking. The product is designed to offer smokers an attractive alternative when they want to quit smoking. After a pharmaceutical approval, the product will be sold as a smoking cessation drug (Nicotine Replacement Therapy – NRT).

Scroll down for more posts ▼

Top 10 Most Recent News Articles

2027 Auto Brand Awards Put Long-Term Buyer Value First Again

Updated Category News Views 48

Car shoppers staring down high prices and financing costs do not need another shiny badge; they need some help separating durable value from showroom wallpaper. That is why the 2027 U.S. News vehicle brand awards, announced Nov. 19, 2026, are worth a look. They are not a sales forecast, not a profit forecast, and certainly not a reason to blindly crown a corporate winner....

Continue Reading
JOYY Q3 Growth Shows More Than Livestreaming Muscle

Updated Category News Views 59

Revenue finally has more than one pair of legs at JOYY, and that matters a whole lot more than a flashy quarterly headline. The company reported third-quarter 2026 revenue of US$624.6 million, up 15.6% from a year earlier and 5.7% from the prior quarter. Those are not microscopic moves, and the composition is the part that deserves the hard stare. JOYY is still rooted in...

Continue Reading
Knowles Expands Its Teacher Pipeline With 39 Fellows

Updated Category News Views 111

Thirty-Nine Teachers Is Not a Trivial Signal Thirty-nine new math and science teachers may not rattle public markets, but it says plenty about where the real strain sits in American education. The Knowles Teacher Initiative has named its 2026 Teaching Fellowship class, its largest ever, and the timing is dead serious: schools are still wrestling with recruiting and...

Continue Reading
American Pride Bank Tests a Fast Southeast Expansion

Updated Category News Views 197

Those old Winston-Salem smokestacks make a fitting backdrop for a bank trying to build something new, and American Pride Bank is moving with uncommon speed. Its new office at 450 N. Patterson Ave., Suite 200 sits in the Bailey South building in Innovation Quarter, across from Bailey Park and amid a district deliberately remade for founders, researchers and growing...

Continue Reading
Subaru's 650-Car Anniversary Bet Is Delightfully Small

Updated Category News Views 112

Gold brake calipers may sound like a fussy correction, yet that little detail tells you exactly who Subaru is trying to please. The company has revised its announcement for the 2027 WRX tS GD25 and BRZ tS ZC15, clarifying the anniversary-model names and changing the WRX description from red-painted to gold-painted Brembo calipers. Nobody should confuse a corrected paint...

Continue Reading
Fidelis Puts $140,000 Behind Statewide Postpartum Care

Updated Category News Views 125

A missed postpartum appointment can look like a small administrative failure until it is not. Fidelis Care’s $140,000 round of Here for Your Health maternal health grants is aimed squarely at that unglamorous but consequential gap: keeping new mothers connected to care after delivery, particularly in underserved New York communities. Small Dollars, Very Specific...

Continue Reading
BLLN Faces Fresh Questions After Short-Seller Report

Updated Category News Views 106

A six-percent air pocket is one thing; a disclosure mismatch is another beast entirely. BillionToOne shares fell on November 18 after short-seller Fuzzy Panda Research alleged the company had not disclosed meaningful regulatory scrutiny, including an alleged Tennessee matter in which regulators suspected fraud in 2024. That is an allegation from a short seller, not a...

Continue Reading
Cold Stone’s Holiday Menu Is a Franchisee Traffic Test

Updated Category News Views 88

Peppermint, caramel, and red velvet arrive right when dessert budgets loosen up. Cold Stone Creamery has rolled out a holiday menu running through January 5, 2027, and this is the sort of modest, practical promotion that matters more to a franchise system than the glittery language around it. Nobody should confuse two seasonal ice cream flavors with a corporate...

Continue Reading
California's AI Oversight Roadmap Raises the Bar Early

Updated Category News Views 89

California has put a real set of teeth on the table, at least on paper. Governor Gavin Newsom's November 18 roadmap for implementing the state's new AI laws embraces an independent verification organization, or IVO, framework that Fathom has been pushing: outside evaluators, licensed by the state, examining whether frontier AI systems create catastrophic risks. For anyone...

Continue Reading
LiberNovo's Black Friday Chair Sale Tests Premium Demand

Updated Category News Views 30

Ergonomic chairs are not impulse purchases, and LiberNovo knows it. Its Black Friday push in the United States and Canada runs through November 30, throwing discounts, gifts, prize-wheel entries and loyalty points at buyers considering a fairly expensive piece of office equipment. That is a lot of promotional machinery for a chair sale, but the underlying pitch is...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring SpaceX's Possible IPO and Its Strategic Implications

Updated Category News Views 194

SpaceX's Strategic Inflection Point SpaceX is signaling preparation for a potential public offering, marking a significant change for one of the most important private companies in the aerospace industry. Although Chief Financial Officer Bret Johnsen has not confirmed an IPO, the message shifts the conversation from mere speculation to a focus on conditional execution....

Continue Reading
Exploring Intel's Options Trading Dynamics and Market Insights

Updated Category News Views 107

Understanding Recent Trends in Intel's Options Market In recent times, significant investors, often referred to as 'whales', have shown a distinct bearish outlook on Intel. Their actions reflect a deeper narrative surrounding the stock and offer a glimpse into market sentiments. Upon analyzing the trading history for Intel (NASDAQ: INTC), we uncovered 31 trades that...

Continue Reading
Surging Growth in the Wasabi Market Driven by Health Benefits

Updated Category News Views 271

Exploring the Growth of the Wasabi Market As consumers become increasingly aware of the numerous health benefits associated with wasabi, the demand for this spicy condiment is on the rise. From 2025 to 2029, the global wasabi market is anticipated to grow by USD 422.2 million, reflecting a remarkable compound annual growth rate (CAGR) of 9.9%. This growth is largely...

Continue Reading
Abel Noser Solutions' Innovative Tool Recognized at Awards

Updated Category News Views 276

Abel Noser Solutions Wins Best Buy-Side TCA Tool Trading Technologies International, Inc. (TT), a leader in capital markets technology, recently announced a remarkable achievement: Abel Noser Solutions has earned the coveted title of Best Buy-Side TCA (Transaction Cost Analysis) Tool in the esteemed Buy-Side Technology Awards 2024. This recognition highlights Abel Noser's...

Continue Reading
Intuitive's Q1 Financial Highlights Show Strong Growth in Revenue

Updated Category News Views 237

Intuitive Surgical Reports Strong First Quarter Financial Performance Intuitive Surgical, a global innovator in robot-assisted surgery, has just unveiled its impressive financial results for the quarter ending March 31, 2025. The company's steady rise in revenue showcases its commitment to improving patient care through advanced technology. Key Highlights from Q1 Results...

Continue Reading